Case Study · Anonymized
Defending the balance sheet at a seven-plant industrial manufacturer.
A $200M PE-backed industrial manufacturer, seven plants across eight sites internationally. A covenant test approaching, reserves nobody could defend, and cost data that told a different story at every site.
The challenge
Multi-site manufacturers accumulate accounting dialects. Each plant books reserves slightly differently, values inventory on its own conventions, and closes on its own rhythm. Consolidated, the result is a number that technically foots and cannot be defended line by line.
That is survivable until something tests it. Here, three things did at once: a debt covenant with a cure obligation attached, a PE sponsor asking harder questions each quarter, and an active merger evaluation that would put every reserve assumption in front of a third-party diligence team.
A reserve you cannot defend is an unpriced liability sitting on your balance sheet, waiting for someone to ask.
The work
Reserve methodology, rebuilt and documented
Inventory, warranty, AR, and accrued liability reserves were re-derived from transaction-level evidence rather than carried forward on precedent. Each position was documented to a standard that would survive an auditor, a lender, and a hostile diligence team, because all three were plausible readers within twelve months.
Cost architecture unified across sites
Standard costing, labor modeling, and overhead absorption were brought onto consistent logic across all seven plants, with BOM analysis and cost variance investigation thresholds defined rather than improvised. Cross-site reporting became comparable for the first time.
Governance written down
Finance and operations policies covering cost accounting, inventory valuation, reserve methodology, and internal controls. Standard operating procedures that materially improved audit readiness and made executive compensation calculations traceable to the same numbers the board was seeing.
Board and sponsor materials
Revenue, variance, and balance sheet analysis packaged into board-ready form and, as importantly, preparing executive leadership for the questions behind the questions. Framing, positioning, and anticipated lines of inquiry ahead of board, audit, merger, and tax discussions.
The result
| Measure | Outcome |
|---|---|
| Reserve adjustments identified and defended | $1M |
| Debt covenant cure obligation averted | $6M |
| Effective return on the reserve position | 6:1 |
| Merger target supported through QofE | $500M |
| Plants brought onto consistent cost logic | 7 |
Quality of earnings, sponsor-side
Partnered with a third-party audit firm and PE principals on QofE analysis for a $500M merger target: EBITDA normalization, bridge construction, and working capital assessment. The same cost architecture discipline that made the home company's numbers defensible is what makes a target's numbers testable.
What transfers
Very little of this is industry-specific. Reserve methodology, overhead absorption, BOM integrity, and close governance behave the same way in fabrication as in contract manufacturing. What changes is where the bodies are buried, and the diagnostic exists to find that quickly rather than assume it.
If a covenant test, a sponsor review, or a diligence process is on your calendar in the next two quarters, the Margin Diagnostic is scoped to tell you what will hold and what will not.
Would your reserves survive a hostile read?
Most finance teams know the answer before they say it out loud. Thirty minutes is usually enough to establish whether the exposure is real and what it would take to close it.